Form 4: Avalo Therapeutics Director Converts RSUs to Stock

Avalo Therapeutics Director Samantha Truex converted 3,166 restricted stock units into common stock on March 28, 2026, increasing her direct beneficial ownership of common stock to 6,333 shares.

Summary

• Samantha Truex, a Director of Avalo Therapeutics, Inc., converted 3,166 restricted stock units (RSUs) into common stock.
• This transaction occurred on March 28, 2026, as part of a predetermined vesting schedule.
• The RSUs convert into common stock on a one-for-one basis.
• Following this conversion, Ms. Truex directly beneficially owns 6,333 shares of Avalo Therapeutics common stock.
• She retains 3,167 restricted stock units, which are scheduled to vest on March 28, 2027.
• The original grant of 9,500 restricted stock units was made on August 13, 2024, with vesting scheduled in three equal annual installments.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting a routine compensation action and continued insider ownership, which generally aligns director interests with shareholders.

Positives

• Director Samantha Truex increased her direct beneficial ownership of common stock by 3,166 shares through the conversion of restricted stock units, bringing her total direct common stock ownership to 6,333 shares.
• The continued vesting and conversion of RSUs demonstrate ongoing commitment and alignment of interests between the director and shareholders.

Future Outlook

The remaining 3,167 restricted stock units held by Samantha Truex are scheduled to vest on March 28, 2027, contingent upon her continued service to the company.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the conversion of equity awards like restricted stock units, are a common and routine part of executive and director compensation in publicly traded companies. This specific transaction reflects a scheduled vesting event rather than a discretionary open-market purchase or sale, which would typically carry more significant signaling value regarding management's immediate outlook on the company's stock.

Stakeholder Impact

• Shareholders: Increased alignment of the director's interests with shareholders through direct stock ownership.

Next Steps

• The remaining 3,167 restricted stock units are scheduled to vest on March 28, 2027, subject to the reporting person's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine vesting and conversion of restricted stock units for a director. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation and does not signal a strong buy or sell opportunity.

Keywords

Avalo Therapeutics, AVTX, Form 4, insider transaction, restricted stock units, RSU conversion, director ownership, beneficial ownership